HCW Biologics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
HCWB Nasdaq 2836 www.hcwbiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for HCW Biologics Inc.

HCW Biologics Announces Pricing of $1.5 Million Private Placement - Sep 24th, 2026 6:25 am
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent - Sep 8th, 2026 7:49 am
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells - Sep 8th, 2026 6:50 am
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - Sep 2nd, 2026 7:00 am
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells - Aug 25th, 2026 7:00 am
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results - Aug 14th, 2026 1:15 pm
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering - Jul 29th, 2026 7:06 am
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 - Jul 23rd, 2026 6:00 am
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Jun 30th, 2026 6:25 am
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 - Jun 26th, 2026 6:55 am
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata - Jun 16th, 2026 5:00 am
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement - May 22nd, 2026 2:02 pm
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules - May 21st, 2026 7:53 am
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners - May 18th, 2026 8:35 am
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results - May 14th, 2026 2:25 pm
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies - May 14th, 2026 5:30 am
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum - Apr 30th, 2026 2:20 pm
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors - Apr 27th, 2026 5:30 am